Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 8-K (Current Report)
Report Date: September 21, 2026
Reporting Period: Three months and transitional fiscal year ended June 30, 2026.
Context: This filing serves to announce the issuance of a press release containing financial results for the specified period. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not embedded within the text of this 8-K form.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not disclosed in the body of this filing.
Material Changes
No material changes regarding financial performance or operational status are detailed in the text of this filing. The document solely references the announcement of results for the transitional fiscal year ended June 30, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release by management but does not include the content of that commentary.
Forward-Looking Statements: The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the period ended June 30, 2026.
- Verify the definition of the "transitional fiscal year" to understand the comparative period length.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached press release.
- Confirm the company's cash runway and burn rate as detailed in the full financial results.